Thummel KE, Lin YS. Sources of interindividual variability. Methods Mol Biol 2014:363–415. https://doi.org/10.1007/978-1-62703-758-7_17

Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: from twin studies to next generation sequencing. Eur J Pharm Sci. 2019;15(130):65–77. https://doi.org/10.1016/j.ejps.2019.01.024.

Article  CAS  Google Scholar 

O’Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012;6(2):251–9. https://doi.org/10.1016/j.molonc.2012.01.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet. 2014;15:349–70. https://doi.org/10.1146/annurev-genom-090413-025419.

Article  CAS  PubMed  Google Scholar 

Schärfe CPI, Tremmel R, Schwab M, Kohlbacher O, Marks DS. Genetic variation in human drug-related genes. Genome Med. 2017;9(1):117. https://doi.org/10.1186/s13073-017-0502-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tafazoli A, Guchelaar H-J, Miltyk W, Kretowski AJ, Swen JJ. Applying next-generation sequencing platforms for pharmacogenomic testing in clinical practice. Front Pharmacol. 2021;12:693453. https://doi.org/10.3389/fphar.2021.693453.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, et al. DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn. 2024;S1525–1578(24):00154–5. https://doi.org/10.1016/j.jmoldx.2024.05.015.

Article  CAS  Google Scholar 

Dean L, Kane M 2021. Fluorouracil therapy and DPYD genotype. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012

Turner RM, Magavern EF, Pirmohamed M. Pharmacogenomics: Relevance and opportunities for clinical pharmacology. Br J Clin Pharmacol. 2022;88(9):3943–6. https://doi.org/10.1111/bcp.15329.

Article  PubMed  Google Scholar 

Xie P, Mo JL, Liu JH, Li X, Tan LM, Zhang W, et al. Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update. Cell Oncol. 2020;43(6):989–1001. https://doi.org/10.1007/s13402-020-00529-1.

Article  CAS  Google Scholar 

Henricks LM, Lunenburg CA, de Man FM, Meulendijks D, Frederix GW, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. The Lancet Oncol. 2018;19(11):1459–67. https://doi.org/10.1016/S1470-2045(18)30686-7.

Article  CAS  PubMed  Google Scholar 

Sirugo G, Williams SM, Tishkoff SA. The missing diversity in human genetic studies. Cell. 2019;177(1):26–31. https://doi.org/10.1016/j.cell.2019.02.048.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan TH, Zhang JE, Pirmohamed M. DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review. Br J Cancer. 2024;131(3):498–514. https://doi.org/10.1038/s41416-024-02754-z.

Article  PubMed  PubMed Central  Google Scholar 

Relling M, Klein T. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–7. https://doi.org/10.1038/clpt.2010.279.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–72. https://doi.org/10.1002/cpt.2350.

Article  PubMed  PubMed Central  Google Scholar 

Drozda K, Pacanowski MA, Grimstein C, Zineh I. Pharmacogenetic labeling of FDA-approved drugs: a regulatory retrospective. JACC Basic Transl Sci. 2018;3(4):545–9. https://doi.org/10.1016/j.jacbts.2018.06.001.

Article  PubMed  PubMed Central  Google Scholar 

Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, et al. Pharmacogenomic information in drug labels: European Medicines Agency perspective. Pharmacogenomics J. 2015;15(3):201–10. https://doi.org/10.1038/tpj.2014.86.

Article  CAS  PubMed  Google Scholar 

European Medicines Agency (EMA) 2020. New testing and treatment recommendations for fluorouracil, capecitabine, tegafur and flucytosine. https://www.emaeuropaeu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-new-testing-treatment_enpdf

Lim SS, Semnani-Azad Z, Morieri ML, Ng AH, Ahmad A, Fitipaldi H, et al. Reporting guidelines for precision medicine research of clinical relevance: the BePRECISE checklist. Nat Med. 2024;30(7):1874–81. https://doi.org/10.1038/s41591-024-03033-3.

Article  CAS  PubMed  Google Scholar 

Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT 15 genotypes: 2018 update. Clin Pharmacol Ther. 2011;89(3):464–7. https://doi.org/10.1038/clpt.2010.279.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lunenburg CA, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28(4):508–17. https://doi.org/10.1038/s41431-019-0540-0.

Article  CAS  PubMed  Google Scholar 

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210–6. https://doi.org/10.1002/cpt.911.

Article  CAS  PubMed  Google Scholar 

The Pharmacogenomics Knowledgebase (PGKB). Annotation of FDA Label for capecitabine and DPYD. Available at: https://www.pharmgkborg/labelAnnotation/PA166104802. Accessed July 2, 2023.

The Pharmacogenomics Knowledgebase (PGKB). Annotation of EMA Label for capecitabine and DPYD. Available at: https://www.pharmgkborg/labelAnnotation/PA166104905. Accessed July 2, 2023.

The Pharmacogenomics Knowledgebase (PGKB). Annotation of EMA Label for tegafur / gimeracil / oteracil and DPYD. Available at: https://www.pharmgkborg/labelAnnotation/PA166271261. Accessed July 2, 2023.

Bank P, Caudle K, Swen J, Gammal R, Whirl-Carrillo M, Klein T, et al. Comparison of the guidelines of the clinical pharmacogenetics implementation consortium and the dutch pharmacogenetics working group. Clin Pharmacol Ther. 2018;103(4):599–618. https://doi.org/10.1002/cpt.762.

Article  CAS  PubMed  Google Scholar 

Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, Committee PS. The Pharmacogene Variation (PharmVar) Consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2018;103(3):399–401. https://doi.org/10.1002/cpt.910.

Article  CAS  PubMed  Google Scholar 

The Pharmacogenomics Knowledgebase (PGKB).PharmGKB Clinical Guideline Annotations. Available at: https://www.pharmgkborg/guidelineAnnotations. Accessed July 2, 2023.

Ramos E, Doumatey A, Elkahloun A, Shriner D, Huang H, Chen G, et al. Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J. 2014;14(3):217–22. https://doi.org/10.1038/tpj.2013.24.

Article  CAS  PubMed  Google Scholar 

Innocenti F, Mills SC, Sanoff H, Ciccolini J, Lenz H-J, Milano G. All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: A practitioner-friendly guide. JCO Oncol Pract. 2020;16(12):793–8. https://doi.org/10.1200/OP.20.00553.

Article  PubMed  PubMed Central  Google Scholar 

Cheung WY, Renfro LA, Kerr D, De Gramont A, Saltz LB, Grothey A, et al. Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the adjuvant colon cancer endpoints database. J Clin Oncol. 2016;34(11):1182–9. https://doi.org/10.1200/JCO.2015.65.1158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whiffin N, Minikel E, Walsh R, O’Donnell-Luria AH, Karczewski K, Alexander Y, et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med. 2017;19(10):1151–8. https://doi.org/10.1038/gim.2017.26.

Article